Physician Views: Will JAK safety concerns limit adoption of Incyte’s Opzelura?

Recent US approval of Incyte’s Opzelura for mild-to-moderate atopic dermatitis is notable for the FDA’s decision to extend recently announced safety labelling for oral JAK inhibitors to this topical medication, and for the stipulating that Opzelura is used only as a short-term and non-continuous chronic treatment.

These safety requirements have raised questions about the commercial opportunity that exists for Opzelura so we are snap-polling US dermatologists and allergists to gain insight into how they anticipate using Incyte’s product and what impact the FDA’s boxed safety warning will have on adoption.

Specifically we are asking them…

  • Whether they intend to prescribe Opzelura
  • To assess efficacy data from Opzelura’s Phase III studies
  • To what extent a black box warning will caution their prescribing of Opzelura
  • Whether the will make a distinction between the FDA’s safety concerns associated with oral JAKs and Opzelura
  • To approximately what percentage of patients under their care with mild-to-moderate atopic dermatitis they would you anticipate prescribing Opzelura to 12 months after its launch

Poll results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.

Reference Articles